Accreditation Information

Accreditation
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medicine (ACCME)
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (UAN 0245-0000-16-003-L01-P).

Nursing (ANCC)
This activity is designated for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

Upon completion of a CE request form, statements of credit for physicians and nurses will be issued via email within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy®(NABP®) CPE Monitor electronic CE tracking system.

Needs Statement

Lung cancer is the most common cancer worldwide as well as the leading cause of cancer-related mortality.1 Of all the subtypes, non-small cell lung cancer (NSCLC) is the most common, comprising 85% of lung cancers.2,3 Despite the diagnostic and therapeutic advancements, NSCLC prognosis remains grim, with only 17.4% of patients surviving five years past diagnosis.4 Recently, there has been a rapid expansion of our knowledge regarding the molecular pathology of NSCLC that has led to the development of targeted therapies, including those targeting epidermal growth factor receptor (EGFR) mutations -- one of the most frequent “actionable” alterations in NSCLC.5,6 With these advancements and expanded treatment options, including the recent FDA approval of the third-generation EGFR tyrosine kinase inhibitor (TKI), new clinical algorithms that take into account individual patient molecular and clinical profiles are needed.

The National Comprehensive Cancer Network and the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology have recently published guidelines and a consensus statement regarding key pathologic, diagnostic, and therapeutic considerations, including optimal choice of EGFR TKI, the role of repeat biopsies, and use of circulating free DNA.7,8,9 Thus, it is imperative for clinicians to stay up-to-date and understand the molecular pathology of NSCLC, when molecular testing is appropriate, and how to interpret test results to guide therapy. Due to this rapidly evolving nature of NSCLC treatment paradigm, all of the members of the oncology team must be knowledgeable about the safety and efficacy of current and emerging NSCLC therapies.

References
1Ferlay J, et al. Int J Cancer. 2015. 2Ettinger DS, et al. J Natl Compr Canc Netw. 2012. 3George J, et al. Nature. 2015. 4National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/lungb/html. 5Cancer Genome Atlas Research. Nature. 2014. 6Berge EM, et al. Semin Oncol. 2014. 7National Comprehensive Cancer Network. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. 8Lindeman NI, et al. J Mol Diagn. 2013. 9Tan DS, et al. J Thorac Onco. 2016.

Objectives

At the conclusion of this application-based activity, participants will be able to:

  • Review the molecular pathology of advanced lung cancer and examine its relevance for clinical practice.
  • Appraise the safety and efficacy of first-line therapies for advanced NSCLC, including chemotherapy and 1st and 2nd generation EGFR TKIs.
  • Evaluate treatment approaches used to overcome EGFR resistance in advanced NSCLC, including the safety and efficacy of second- and third-line therapies.
  • Differentiate recommended molecular testing and role for ctDNA in detecting EGFR mutations, including T790M.

Target Audience

Hospital-based clinicians involved in the care of patients with non-small cell lung cancer (NSCLC) including oncologists, oncology residents/fellows, oncology specialty nurse practitioners, nurses, nurse navigators, physician assistants, and pharmacists.

Faculty Disclosure

Planner and Faculty Disclosures:
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:
Vanessa Carranza, PharmD – has no relevant financial relationships to disclose in relation to the content of this activity.

Roy S. Herbst, MD, PhD – is a consultant for AstraZeneca, Lilly, Genentech/Roche, Gilead, Merck and Pfizer; receives grant/research support from Genentech and Meck; and is a member of the scientific advisory boards for Biothera, Diatech, and Kolltan.

Josiah Land, PharmD, BCOP – has no relevant financial relationships to disclose in relation to the content of this activity.

Rachael B. Pollina, MS, MSN, RN, OCN®, FNP-BC – has no relevant financial relationships to disclose in relation to the content of this activity.

Authors/Presenters:
Hossein Borghaei, DO – is a consultant for Bristol-Myers Squibb, Celgene, EMD-Serono, Genentech, Lilly, and Pfizer, and receives research/grant support from Celgene, Merck, and Millennium.

Paul A. Bunn, Jr, MD, FASCO – is a consultant for AstraZeneca, Boehringer Ingelheim, Clovis, and Genentech.

David S. Ettinger, MD, FACP, FCCP – disclosures to come

Justin F. Gainor, MD – is a consultant for ARIAD, Bristol-Myers Squibb, Boehringer Ingelheim, Clovis, Genentech, Incyre, Loxo, Merck, Novartis, and Theravance.

David R. Gandara, MD – is a consultant for ARIAD, AstraZeneca, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Mirati, Novartis, and Pfizer, and receives research/grant support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Clovis, Genentech, Johnson and Johnson, Lilly, Merck, and Novartis.

David Gerber, MD - has disclosed he has received research funding from ArQule, Boehringer-Ingelheim, BerGenBio, Celgene, Genentech, ImmunoGen, Karyopharm, and Peregrine. He has also participated on advisory boards for Boehringer-Ingelheim, Bristol Myers-Squibb Company, MS, Celgene, Genentech, Guardant, Peregrine, Samsung, Synta, and AstraZeneca.

Ramaswamy Govindan, MD – is a consultant for ARIAD, Astellas, Bayer, Celgene, Clovis, Genentech, GlaxoSmithKline, Helsinn, and Roche, and is a member of the speakers’ bureaus for Baxalta, Celgene, Pfizer, and Roche.

Fred R. Hirsch, MD, PhD – has participated on scientific advisory boards for AstraZeneca, Boehringer Engelheim, Bristol-Myers Squibb, Genentech/Roche, Lilly, Merck, Pfizer, and Ventana and his institution, the University of Colorado, receives grant/research support from Amgen, Bayer, Bristol-Myers Squibb, Genentech/Roche, Lilly, and Merck.

Mark G. Kris, MD, FACP, FACCP – has no relevant financial relationships to disclose in relation to the content of this activity.

Corey J. Langer, MD – Dr. Langer serves as a scientific advisor for Bristol-Myers Squibb, ImClone Systems, Pfizer, Eli Lilly, AstraZeneca, Novartis, Genentech, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Abraxis Oncology (Celgene), Abbott, Biodesix, Clariant, CarisDx, ARIAD, Boehringer Ingelheim, Synta, and Clovis. He receives institutional grant/research support from Bristol-Myers Squibb, ImClone Systems, Pfizer, Eli Lilly, Genentech, OSI, GlaxoSmithKline, Clovis, Merck, Nektar, Advantagene, Inovio, and Ariad. He is a member of Data and Safety Monitoring Committee for Amgen, Synta, Peregrine, SWOG, and Incyte.

Vassiliki A. Papadimitrakopoulou, MD – is a consultant for ARIAD, AstraZeneca, Biothera, Bristol-Myers, Squibb, Genentech, Johnson and Johnson, and Merck. She receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Johnson and Johnson, Merck, and Novartis.

Suresh S. Ramalingam, MD – is a consultant for Abbvie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Genentech, Lilly, Merck, and Novartis.

Naiyer Rizvi, MD – is a consultant for AstraZeneca, Merck, Novartis, and Roche, and is a shareholder/co-founder of Gritstone Oncology.

Lecia V. Sequist, MD, MPH – is a consultant for Ariad, AstraZeneca, Boehringer Ingelheim, Clovis, Merrimack, and Novartis.

Mark A. Socinski, MD – receives grant/research support from Bristol-Myers Squibb, Celgene, Clovis, Genentech, and Pfizer, and is a member of the speakers’ bureaus for Bristol-Myers Squibb, Celgene, and Genentech.

Thomas E. Stinchcombe, MD – is a consultant for ARIAD, Boehringer Ingelheim, Bristol-Myers Squibb, and Helsinn, and receives grant/research support from Bristol-Myers Squibb, Genentech, and Merck Serono.

Howard (Jack) West, MD – is a consultant for AstraZeneca, Boehringer Ingelheim, Genetech/Roche, Guardant, and Trovagene, and is a member of the speakers’ bureau for Genentech/Roche.

Reviewers:
Corey J. Langer, MD – Dr. Langer serves as a scientific advisor for Bristol-Myers Squibb, ImClone Systems, Pfizer, Eli Lilly, AstraZeneca, Novartis, Genentech, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals, Abraxis Oncology (Celgene), Abbott, Biodesix, Clariant, CarisDx, ARIAD, Boehringer Ingelheim, Synta, and Clovis. He receives institutional grant/research support from Bristol-Myers Squibb, ImClone Systems, Pfizer, Eli Lilly, Genentech, OSI, GlaxoSmithKline, Clovis, Merck, Nektar, Advantagene, Inovio, and Ariad. He is a member of Data and Safety Monitoring Committee for Amgen, Synta, Peregrine, SWOG, and Incyte.

Vassiliki A. Papadimitrakopoulou, MD – is a consultant for ARIAD, AstraZeneca, Biothera, Bristol-Myers, Squibb, Genentech, Johnson and Johnson, and Merck. She receives grant/research support from AstraZeneca, Bristol-Myers Squibb, Genentech, Johnson and Johnson, Merck, and Novartis.

Sarah S. Peters, PharmD, MPH, BCOP – is a consultant for Genentech, and is a member of the speakers’ bureaus for Eli Lilly, Merck, Pfizer, and Boehringer-Ingelheim.

Victoria Sherry, DNP, CRNP, ANP-BC, AOCNP - has no relevant financial relationships to disclose in relation to the content of this activity.